Day One Biopharmaceuticals (DAWN) Leases (2022 - 2025)
Day One Biopharmaceuticals (DAWN) has disclosed Leases for 4 consecutive years, with $2.3 million as the latest value for Q4 2025.
- On a quarterly basis, Leases fell 3.3% to $2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.3 million, a 3.3% decrease, with the full-year FY2025 number at $2.3 million, down 3.3% from a year prior.
- Leases was $2.3 million for Q4 2025 at Day One Biopharmaceuticals, down from $2.4 million in the prior quarter.
- In the past five years, Leases ranged from a high of $2.6 million in Q1 2025 to a low of $164000.0 in Q2 2024.
- A 4-year average of $1.2 million and a median of $781500.0 in 2022 define the central range for Leases.
- Peak YoY movement for Leases: crashed 69.06% in 2024, then surged 1423.78% in 2025.
- Day One Biopharmaceuticals' Leases stood at $699000.0 in 2022, then tumbled by 49.64% to $352000.0 in 2023, then skyrocketed by 588.07% to $2.4 million in 2024, then decreased by 3.3% to $2.3 million in 2025.
- Per Business Quant, the three most recent readings for DAWN's Leases are $2.3 million (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).